All Programs

Use the tool below to view all available Global Neurology Academy Series

Rethinking Schizophrenia Guidelines: Why It’s Time to Incorporate Novel Mechanisms
Rethinking Schizophrenia Guidelines: Why It’s Time to Incorporate Novel Mechanisms
NeuroFrontiers
Rethinking Schizophrenia Guidelines: Why It’s Time to Incorporate Novel Mechanisms
- Charles Turck, PharmD, BCPS, BCCCP
- Desiree Matthews, PMHNP-BC
Bridging the Diagnostic Gap: Blood Biomarkers in Alzheimer’s Care
Bridging the Diagnostic Gap: Blood Biomarkers in Alzheimer’s Care
NeuroFrontiers
Bridging the Diagnostic Gap: Blood Biomarkers in Alzheimer’s Care
- Ashvini Keshavan, MRCP, PhD
Bridging Inpatient to Outpatient Schizophrenia Care: Solutions for Safer Transitions
Bridging Inpatient to Outpatient Schizophrenia Care: Solutions for Safer Transitions
NeuroFrontiers
Bridging Inpatient to Outpatient Schizophrenia Care: Solutions for Safer Transitions
- Shelina Ramnarine, PhD
- Michelle Scargle, MD
- Margaret Emerson, DNP, APRN, PMHNP-BC
Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease
Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease
NeuroFrontiers
Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease
- Sharon Sha, MD, MS
Using fMRI to Identify Early Alzheimer’s Disease Subgroups
Using fMRI to Identify Early Alzheimer’s Disease Subgroups
NeuroFrontiers
Using fMRI to Identify Early Alzheimer’s Disease Subgroups
- Hamid Abuwarda, PhD, BS
Engaging Patients and Caregivers in Schizophrenia: A Collaborative Care Approach
Engaging Patients and Caregivers in Schizophrenia: A Collaborative Care Approach
NeuroFrontiers
Engaging Patients and Caregivers in Schizophrenia: A Collaborative Care Approach
- Shelina Ramnarine, PhD
- Apurva Bhatt, MD
- Shannon Pagdon, BA
Understanding the Caregiver Burden in TK2 Deficiency: New Insights from a Study
Understanding the Caregiver Burden in TK2 Deficiency: New Insights from a Study
Clinician's Roundtable
Understanding the Caregiver Burden in TK2 Deficiency: New Insights from a Study
- Charles Turck, PharmD, BCPS, BCCCP
- Philip Yeske, PhD
Uncovering the Disease Burden of Untreated Pediatric TK2 Deficiency
Uncovering the Disease Burden of Untreated Pediatric TK2 Deficiency
Clinician's Roundtable
Uncovering the Disease Burden of Untreated Pediatric TK2 Deficiency
- Charles Turck, PharmD, BCPS, BCCCP
- Cristina Domínguez González, MD, PhD
Individualizing gMG Treatment: Defining Success With Each Patient
Individualizing gMG Treatment: Defining Success With Each Patient
NeuroFrontiers
Individualizing gMG Treatment: Defining Success With Each Patient
- Omar Sinno, MD
Timing Meningococcal Vaccines in gMG: Challenges and Considerations
Timing Meningococcal Vaccines in gMG: Challenges and Considerations
NeuroFrontiers
Timing Meningococcal Vaccines in gMG: Challenges and Considerations
- Michael Weiss, MD
Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape
Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape
CME/CE
Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape
1.00 credit
- Stephen Chrzanowski, MD, PhD
- Aravindhan Veerapandiyan, MD
1.00 credit
Advancing MS Care: Diagnostic Clarity, Early Action, and Patient-Centered Treatment
Advancing MS Care: Diagnostic Clarity, Early Action, and Patient-Centered Treatment
Global Neurology Academy
Advancing MS Care: Diagnostic Clarity, Early Action, and Patient-Centered Treatment
- Tirisham V. Gyang, MD
- Gates B. Colbert, MD
Genetic Testing in Pediatrics: Identifying Neurodevelopmental Disorders Early
Genetic Testing in Pediatrics: Identifying Neurodevelopmental Disorders Early
Clinician's Roundtable
Genetic Testing in Pediatrics: Identifying Neurodevelopmental Disorders Early
- Jennifer M. Kalish, MD, PhD, FAAP
Navigating MS Diagnosis in Older Adults: Distinguishing Comorbidities and Mimics
Navigating MS Diagnosis in Older Adults: Distinguishing Comorbidities and Mimics
NeuroFrontiers
Navigating MS Diagnosis in Older Adults: Distinguishing Comorbidities and Mimics
- Le Hua, MD
Genetic Pathways in MS: The Clinical Impact of a Chromosome 2 Variant
Genetic Pathways in MS: The Clinical Impact of a Chromosome 2 Variant
NeuroFrontiers
Genetic Pathways in MS: The Clinical Impact of a Chromosome 2 Variant
- Sergio Baranzini, PhD
Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
NeuroFrontiers
Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
- Michael Levy, MD, PhD

All Programs

Popular

NEED HELP?

Contact us

NEED HELP?

Contact us

All Programs

Popular

Title

Share on ReachMD